Proteasome inhibitors: all 957 studies that test it

Page 2 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple MyelomaCompletedNCT03170882Phase 2Results posted
• Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideTerminatedNCT03117361Phase 2Results posted
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT03110562Phase 3Results posted
• Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic MalignanciesCompletedNCT03082677Phase 2Results posted
• Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Phase 3Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03012880Phase 2Results posted
• Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedNCT02969837Phase 2Results posted
• A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple MyelomaCompletedNCT02951819Phase 2Results posted
• The Effect of Ixazomib on the Latent HIV ReservoirCompletedNCT02946047Phase 1/2Results posted
• High Dose Carfilzomib for Newly Diagnosed MyelomaCompletedNCT02937571Phase 1/2Results posted
• Ixazomib Rollover StudyCompletedNCT02924272Phase 2Results posted
• A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02917941Phase 2Results posted
• Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple MyelomaCompletedNCT02916771Phase 2Results posted
• Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2Results posted
• Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaTerminatedNCT02898259Phase 1/2Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple MyelomaCompletedNCT02874742Phase 2Results posted
• Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementCompletedNCT02765854Phase 2Results posted
• Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)CompletedNCT02703779Phase 2Results posted
• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple MyelomaCompletedNCT02654990Phase 2Results posted
• Phase 0 Analysis of Ixazomib (MLN9708) in Patients With GlioblastomaCompletedNCT02630030Early Phase 1Results posted
• Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02619682Phase 2Results posted
• High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple MyelomaCompletedNCT02597062Phase 2Results posted
• Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IActive, not recruitingNCT02553460Phase 1/2Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL AmyloidosisCompletedNCT02545907Phase 1/2Results posted
• Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple MyelomaCompletedNCT02542657Phase 1/2Results posted
• Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young AdultsTerminatedNCT02535806Phase 2Results posted
• Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedNCT02518750Phase 2Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BoneTerminatedNCT02516423Phase 3Results posted
• Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host DiseaseCompletedNCT02513498Phase 2Results posted
• UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib TreatmentCompletedNCT02499081Phase 2Results posted
• Carfilzomib in Treating Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT02491359Phase 2Results posted
• Trial of High Dose Melphalan/Stem Cell Transplant With or Without BortezomibTerminatedNCT02489500Phase 3Results posted
• Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple MyelomaCompletedNCT02481934Phase 1Results posted
• Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT02481310Phase 1/2Results posted
• Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung TransplantationCompletedNCT02474927Phase 2Results posted
• Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)TerminatedNCT02447887Phase 1/2Results posted
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaCompletedNCT02441686Phase 2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)CompletedNCT02440464Phase 2Results posted
• Optimising Renal Outcome in Myeloma Renal FailureCompletedNCT02424851Phase 2Results posted
• Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesTerminatedNCT02419755Phase 2Results posted
• Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple MyelomaCompletedNCT02412878Phase 3Results posted
• Ixazomib, Cyclophosphamide and Dexamethasone for Multiple MyelomaCompletedNCT02412228Phase 2Results posted
• Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaCompletedNCT02400437Phase 2Results posted
• Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell TransplantCompletedNCT02389517Phase 2Results posted
• Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary FibrosisCompletedNCT02370693Phase 2Results posted
• Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaTerminatedNCT02353572Phase 1/2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT02353468Phase 2Results posted
• Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasCompletedNCT02341014Phase 1/2Results posted
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02339922Phase 2Results posted
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02335983Phase 1Results posted
• Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabCompletedNCT02330562Phase 1/2Results posted
• Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine CancersCompletedNCT02318784Phase 2Results posted
• A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Phase 3Results posted
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionTerminatedNCT02302846Phase 2Results posted
• Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT02290431Phase 2Results posted
• Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaActive, not recruitingNCT02253316Phase 2Results posted
• MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic TransplantationCompletedNCT02250300Phase 1/2Results posted
• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02224729Phase 2Results posted
• Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell TransplantCompletedNCT02181413Phase 3Results posted
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)TerminatedNCT02176486Phase 1Results posted
• Nonmyeloablative Haploidentical Transplant Followed by MLN9708CompletedNCT02169791Phase 2Results posted
• Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple MyelomaCompletedNCT02168101Phase 2Results posted
• Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell LymphomasCompletedNCT02158975Phase 2Results posted
• Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple MyelomaCompletedNCT02148913Phase 1Results posted
• Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic MalignanciesCompletedNCT02145403Phase 1/2Results posted
• Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory NeuroblastomaCompletedNCT02139397Phase 1/2Results posted
• Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT02119468Phase 1/2Results posted
• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaActive, not recruitingNCT02112916Phase 3Results posted
• Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple MyelomaCompletedNCT02100657Phase 1Results posted
• Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell LymphomaCompletedNCT02073097Phase 1/2Results posted
• MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple MyelomaCompletedNCT02057640Phase 1/2Results posted
• Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following TreatmentCompletedNCT02047253Phase 2Results posted
• Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple MyelomaCompletedNCT02046070Phase 2Results posted
• A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT02042950Phase 2Results posted
• Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
• Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02030405Phase 2Results posted
• Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line TherapyTerminatedNCT02020941Phase 2Results posted
• Carfilzomib With Bendamustine and Dexamethasone in Multiple MyelomaTerminatedNCT02002598Phase 1/2Results posted
• A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaTerminatedNCT01999335Phase 1Results posted
• Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung CancerCompletedNCT01987232Phase 1/2Results posted
• A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01980589Phase 1Results posted
• Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple MyelomaTerminatedNCT01969565Phase 2Results posted
• Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01962792Phase 1/2Results posted
• Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell LymphomaActive, not recruitingNCT01959698Phase 1Results posted
• Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIBCompletedNCT01953783Phase 1Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic ImpairmentCompletedNCT01949545Phase 1Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal DiseaseCompletedNCT01949532Phase 1Results posted
• Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer PatientsCompletedNCT01941316Phase 1/2Results posted
• Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular LymphomaCompletedNCT01939899Phase 2Results posted
• Bortezomib to Treat Significant Complication of HSCTCompletedNCT01929980Phase 2Results posted
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple MyelomaCompletedNCT01919086Phase 2Results posted
• Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver DysfunctionCompletedNCT01912222Phase 1Results posted
• S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory MyelomaCompletedNCT01903811Phase 2Results posted
• Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 ActivationCompletedNCT01891968Phase 2Results posted
• Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute LeukemiaTerminatedNCT01887587Phase 1Results posted
• Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisCompletedNCT01864018Phase 1/2Results posted
• Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) ProphylaxisCompletedNCT01860170Phase 1/2Results posted

← Proteasome inhibitors overview